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INTRODUCTION
Pleural effusion is associated with both benign and
malignant diseases. It is divided into exudative ef-
fusion and transudative effusion (1). While transu-
dative effusion is mainly seen in patients with heart
failure, renal failure, and liver cirrhosis, exudative
effusion is seen in patients with various diseases,
including malignant diseases, pneumonia, pulmonary
tuberculosis, and collagen diseases (1-4). In particu-
lar, malignant effusion is seen frequently in patients
with lung cancer and is known as a marker of poor
prognosis for the patients (5). Therefore, the man-
agement of pleural effusion is clinically important.
Pleural effusion formation is multifactorial. At least,
pleural effusion formation is associated with 1) im-
paired drainage of the pleural space due to obstruc-
tion of vessels and lymphatics of the lungs and
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pleura, and 2) increased pleural fluid formation (6-8).
Considering the latter mechanism, vascular endo-
thelial growth factor (VEGF), a 34 to 42-kDa dimeric
protein, is a potent mediator (9, 10). Initially discov-
ered because of its ability to increase vascular per-
meability, the molecule was first called vascular per-
meability factor (VPF) (11). We previously reported
that exudative pleural effusions associated with lung
cancer contained significantly higher amounts of
VEGF than transudative pleural effusions (8). In ad-
dition, tumor-cell derived VEGF facilitated the pro-
duction of bloody pleural effusions by inducing hy-
perpermeability in the thoracic cavity (12), indicat-
ing the critical role of VEGF in the production of
bloody malignant pleural effusions. However, the
presence of other cofactors or inhibitors with VEGF/
VPF might regulate pleural fluid formation.
In addition, the biological activity of VEGF has
been previously been documented to be modified
or regulated by several VEGF-related molecules. For
example, VEGF binds to specific receptors, such as
VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR), and
this binding is augmented by the presence of co-
receptors (neuropilin-1 and -2) (9, 13, 14). VEGFR-
2-mediated signaling is thought to be necessary for
fully expressing biological function of VEGF. VEGFR-
1 acts as a negative regulator of VEGF activity, as
VEGF-mediated stimulation of VEGFR-1 autophos-
phorylation is weak in endothelial cells, while VEGFR-
1 has 10 times higher affinity to VEGF than VEGFR-
2 (15). Much attention has been paid to a naturally
occurring, alternatively spliced soluble form of
VEGFR-1 (sVEGFR-1). sVEGFR-1 binds to VEGF
with high affinity and neutralizes VEGF activity (16,
17). sVEGFR-1 is reported to present in the serum
and amniotic fluid of pregnant women, but it is un-
known whether sVEGFR-1 exists in pleural effusion
(18-20).
Angiopoietin (Ang)-1 and -2 have been identified
as ligands for Tie-2, which is a receptor tyrosine
kinase specifically expressed on endothelial cells,
and Angs play critical roles in angiogenesis in con-
cert with VEGF (21-23). Ang-1 binds to Tie-2 and
maintains and stabilizes mature vessels by promot-
ing the interaction between endothelial cells and
surrounding extracellular matrix (23). Ang-2 com-
petitively binds to Tie-2, and antagonizes the stabi-
lizing action of Ang-1, which results in destabiliza-
tion of vessels (22, 23). Recent studies reported that
Ang-2 induced peritoneal bleeding in hepatic tumor
models. In addition, elevated levels of Ang-2, but not
Ang-1, have recently been reported to exist in exu-
dative pleural effusion (24). However, the role of Ang-
2 or relationship of Ang-2 with sVEGFR-1 in pleural
effusion is not fully understood.
In the present study, we examined the levels of
sVEGFR-1 and Ang-2 as possible regulators of VEGF
activity in transudative and exudative pleural effu-
sions. The significance of these VEGF-associated
molecules in pleural effusion is herein discussed.
MATERIALS AND METHODS
Reagents.
Recombinant VEGF165 was obtained from R&D
Systems (Inc., Minneapolis, MN), and Recombinant
sVEGFR-1 from Fitsgerald Industries International
(Inc.,Concord,MA).
Patient Characteristics.
A total of 42 pleural fluid samples, obtained from
patients (34 males and 8 females) who underwent
thoracentesis in Tokushima University Hospital be-
tween April 2001 and February 2005, were examined
after written informed consent had been obtained
(Table 1). The mean age of the patients was 63.6±
14 years. A pleural effusion was categorized as ma-
lignant if the results of pleural fluid cytology test-
ing or pleural biopsy were positive for malignancy
or if the patient had a known metastatic malignancy
without other cause for the effusion. The 32 patients
in the malignant effusion group were diagnosed as
follows : Primary lung carcinomas - 22 (4 small cell,
12 adenocarcinoma, 4 squamous cell, 2 large cell),
Malignant mesothelioma - 2, Malignant lymphoma - 2,
Adult T-cell leukemia - 1, Renal cancer - 1, Epipha-
ryngial cancer - 1, Acral myxoinflammatory fibro-
blastic sarcoma - 1, Skin cancer (squamous cell car-
cinoma) - 1, Adenocarcinoma of unknown origin - 1.
Tuberculous pleuritis (n=6) was categorized as one
that was either microbiologically positive or a tuber-
culous lesion in pleural biopsy or purulent fluid with
pulmonary tuberculosis which had no features of
bacterial pneumonia and malignant. Pleural effusion
with cardiac insufficiency (n=4) was categorized as
a type of transudative effusion in a patient with symp-
toms and signs of CHF who responded to appropri-
ate therapy.
Measurements of VEGF, Ang-2, and sVEGFR-1.
After thoracentesis, pleural fluid was collected and
submitted to routine laboratory examinations, includ-
ing the appearance (bloody or non-bloody), a protein
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analysis, and a lactate dehydrogenase analysis.
For the measurement of VEGF, sVEGFR-1, and
Ang-2, the pleural fluids were immediately centri-
fuged at 1200 rotations/min for 7 min at 4℃, and the
supernatant was stored at -80℃ until analysis. The
levels of VEGF, sVEGFR-1 and Ang-2 were deter-
mined using sandwich ELISA kits (R&D Systems,
Inc., Minneapolis, MN) according to the manufac-
turers instructions.
Statistical Analysis.
Mann-Whitney tests were used throughout the
study to compare individual groups. The correlation
was analyzed with the Speaman correlation test. The
criterion of statistical significance was p < 0.05. Sta-
tistical significance was analyzed using GraphPad
Prism software program Ver.4.01.
RESULTS
Measurement of sVEGFR-1 bound to VEGF by
ELISA.
In the first set of experiments, we determined
whether VEGF-sVEGFR-1 complex was measured
by ELISA for VEGF and sVEGFR-1. Recombinant
VEGF165 and recombinant sVEGFR-1 were incu-
bated in medium with 10% FBS for 1 hour at 37℃,
and the resultant solutions were measured by ELISA
for VEGF and sVEGFR-1, respectively. As shown in
Fig. 1A, B, the addition of VEGF did not affect the
level of sVEGFR-1, thus suggesting that sVEGFR-
1 values determined by this ELISA contain free
sVEGFR-1 and sVEGFR-1 bound to VEGF. On the
Fig. 1. Measurement of sVEGFR-1 bound to VEGF by ELISA.
Recombinant VEGF 165 and recombinant sVEGFR-1 were in-
cubated in medium with 10% FBS for 1 hour at 37℃, and the
resultant solutions were measured by ELISA for VEGF and
sVEGFR-1, respectively.
Table 1 Characteristics and Laboratory Findings of the Subjects
LC (n=22) Ma (n=10) Tb (n=6) HF (n=4)
Gender Male 18 8 4 4
Female 4 2 2 0
Age average 65 59.6 64.6 64.3
range 42-92 19-89 31-86 56-71
LDH (IU/L) average 631 416 225 180
range 108-1852 95-1775 137-365 111-209
LDH ratio average 2.98 1.5 2.2 0.45
range 0.5-8.87 0.74-3.29 0.74-3.29 0.31-0.56
Protein (g/dL) average 4.02 3.13 3.45 1.48
range 1.88-5.56 1.41-4.77 1.61-5.01 0.14-2.96
Appearance bloody 14 6 1 1
non-bloody 8 4 5 3
VEGF (ng/ml) average 3.12 0.8 0.47 0.087
range 0.016-22.5 0.025-2.66 0.005-2.73 0-0.34
Ang-2 (ng/ml) average 39.9 41.9 19.7 10.5
range 5.65-82.5 15.1-93.9 13.2-30.6 8.38-13.7
sVEGFR-1 (ng/ml) average 0.722 0.967 6.76 0
range 0-4.57 0-5.41 0.007-35.9 0
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other hand, the addition of sVEGFR-1 resulted in a
decrease in the level of VEGF, thus suggesting that
VEGF values determined by this ELISA indicate free
VEGF.
Levels of VEGF, sVEGFR-1, and Ang-2 in exudative
and transudative effusion.
We next measured the levels of VEGF, sVEGFR-
1, and Ang-2 in the pleural effusions from 42 patients,
and compared the levels in exudative effusions and
transudative effusions. Since the ratio of LDH in the
pleural effusion/LDH in the serum is commonly
used as a marker to distinguish exudative effusion
from transudative effusion, we considered such ef-
fusion to be exudative when a ratio of more than 0.6
was observed. According to the results of previous
reports, the levels of VEGF and Ang-2 in exudative
effusion were higher than those in transudative ef-
fusion (Fig. 2 A, B). Moreover, the levels of sVEGFR-
1 were also higher in the exudative effusions com-
pared with transudative effusions (Fig. 2 C).
Bloody effusion is frequently associated with ma-
lignant diseases. Interestingly, the levels of VEGF
and Ang-2 in bloody effusion were significantly higher
than those in non-bloody effusion (p < 0.05) (Fig. 3
A, B). In contrast, the level of sVEGFR-1 in bloody
effusion was lower than that in non-bloody effusion
(Fig. 3C).
Comparison of the levels of VEGF, Ang-2, and
sVEGFR-1 in the pleural effusions between the dis-
ease groups.
We next compared the levels of VEGF, Ang-2, and
sVEGFR-1 in the pleural effusion among various
diseases. As shown in Fig. 4A～C and Table 1, the
levels of VEGF and Ang-2 were significantly higher
in the effusion from LC and MD, compared with
effusion from HF and TB (p < 0.05). In addition,
sVEGFR-1 was significantly higher in the effusion
from LC, MD, and TB compared with effusion from
HF (p < 0.05).
Correlation of the levels of VEGF, Ang-2, and/or
sVEGFR-1 in malignant pleural effusions.
Since the high levels of VEGF, Ang-2, and
sVEGFR-1 were detected in malignant effusions,
we further evaluated the correlation of these three
factors in malignant effusions by the Speaman cor-
relation test analyses. There are direct correlations
between VEGF and Ang-2, VEGF and sVEGFR-1,
and sVEGFR-1 and Ang-2 (Fig. 5A～C).
Fig. 2. Levels of VEGF, sVEGFR-1, and Ang-2 in exudative and
transudative effusions. Horizontal lines represent the median
values.
Fig. 3. Levels of VEGF, sVEGFR-1, and Ang-2 in bloody- and
non-bloody effusions. Horizontal lines represent the median
values.
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DISCUSSION
We recently reported that VEGF presented within
exudative pleural effusion, and it facilitated the pro-
duction of bloody pleural effusion by inducing vas-
cular hyperpermeability in the thoracic cavity (12).
In addition, Ang-2 was shown to present in the exu-
dative effusion (24). In the present study, we con-
firmed that higher levels of VEGF and Ang-2 existed
in the exudative effusion compared with transuda-
tive effusion, and further demonstrated that an en-
dogenous inhibitor of VEGF, sVEGFR-1, also existed
in the exudative effusion. Moreover, higher levels
of VEGF and Ang-2 were detected in the bloody ef-
fusion than in the non-bloody effusion. In contrast,
sVEGFR-1 levels in bloody effusion were lower than
that in non-bloody effusion, suggesting the regula-
tory role of sVEGFR-1 in the exudative pleural ef-
fusion.
sVEGFR-1, found in trophoblasts and endothelial
cells of normal placental tissue, was abnormally de-
tected in the serum of preeclamptic patients (25).
Clinical symptoms in preeclamptic patients are simi-
lar with the side effects of VEGF neutralizing anti-
body in cancer patients (26, 27), thus suggesting that
the preeclamptic symptoms on the maternal side are
due to an abnormal suppression of endogenous VEGF
by sVEGFR-1. Therefore, sVEGFR-1 is thought to
regulate or modulate VEGF activity as an endoge-
nous inhibitor. Recent clinical trials showed thera-
peutic potential of VEGF/VEGFR inhibitors, in-
cluding anti-VEGF antibody (bevacizumab), against
various solid tumors, including renal cell carcinoma
and non-small cell lung cancer (17, 28, 29).
It is thought that bloody pleural effusions result
from vascular wall rupture or leakage of blood cells.
The bloody pleural effusions are observed frequently
and associated with both of benign and malignant
disease. We found that the level of VEGF in the
bloody effusions was higher than that in the non-
bloody effusions. On the other hand, the level of
sVEGFR-1 in the bloody effusions was lower than
that in the non-bloody effusions. Since sVEGFR-1 is
an endogenous inhibitor of VEGF (16, 17), sVEGFR-
1 might be produced by host cells in response to
suppression of VEGF activity. If the production level
of sVEGFR-1 is insufficient, then bloody effusion
might be produced because of the high VEGF ac-
tivity. Further studies are warranted to examine this
hypothesis.
Ang-2 has been shown to be involved in the patho-
genesis of a variety of human diseases including can-
Fig. 4. The levels of VEGF, Ang-2, and sVEGFR-1 in the
pleural effusions due to lung cancer (LC), other malignant dis-
eases (MD), tuberculosis (TB), and heart failure (HF). Hori-
zontal lines represent the median values.
Fig. 5. Correlation of the levels of VEGF, Ang-2, and/or
sVEGFR-1 in malignant pleural effusions.
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cer, diabetic retinopathy, pulmonary hypertension,
and coronary artery disease (30-33). Concerning ma-
lignant diseases, Ang-2 induces the instability of the
blood vessels and facilitates the angiogenesis in the
presence of VEGF, and it is one of the poor prognos-
tic factors of non-small cell lung cancer (34). More-
over, a recent report showed that Ang-2 was sup-
posed to be produced locally in the pleural space,
and that elevated levels of Ang-2, as well as VEGF,
in exudative pleural effusions were detected. How-
ever, the functional significance of Ang-2 in pleural
disease is poorly understood. We confirmed that a
high level of VEGF and Ang-2 coexisted in the exu-
dative effusion, especially bloody effusion. Moreover,
there was a direct correlation between the levels of
VEGF and Ang-2. Since Ang-2 overexpression in he-
patocellular carcinoma caused the abdominal bleed-
ing in orthotopic animal models (35), VEGF and Ang-
2 might thus synergistically induce not only angio-
genesis, but also vascular hyperpermeability.
In the present study, the cellular origins of the
VEGF, Ang-2, and sVEGFR-1 were not determined
because of the lack of the corresponding tissue sam-
ples and techniques to detect these factors appro-
priately. However, several lines of evidence show
that VEGF is produced by various types of cells, in-
cluding tumor cells, muscle cells, pericytes, glia cell,
and fibroblasts (9). Ang-2 is mainly produced by
endothelial cells and cancer cells (22). sVEGFR-1
is mainly produced by trophoblasts (18-20), but it
might be produced by endothelial cells and macro-
phages because these cells express sVEGFR-1 (36).
Lung cancer is the leading cause of malignant pleu-
ral effusion (37). At least 25% of all patients with lung
cancer tend to develop pleural effusion at some time
during the course of the disease. The standard treat-
ment for malignant pleural effusion is drainage fol-
lowed by the instillation of sclerosing agents, but the
clinical efficacy of this treatment varies (38). VEGF/
VPF is reported to be responsible for malignant pleu-
ral effusion formation and targeting the production
of VEGF/VPF and/or blocking the VEGF/VPF re-
ceptor may be a way to control malignant pleural ef-
fusion. In addition to the anti-VEGF antibody (bevaci-
zumab) which has been shown to have a therapeu-
tic potential against non-small cell lung cancer, an
endogenous VEGF inhibitor, sVEGFR-1, may be
useful for controlling the malignant pleural effusion
associated with VEGF-induced vascular hyperper-
meability.
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